Loss of TGFBI induced specific resistance to paclitaxel in ovarian cancer cells, and paclitaxel-resistant cells treated with recombinant TGFBI protein show restoration of paclitaxel sensitivity (37). Here, TGFBI is linked to ovarian carcinoma.